Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Millendo Therapeutics amendments of at-the-market offering program
Davis Polk advised the sales agents in connection with certain amendments of the SEC-registered at-the-market offering…
J M Smith sale of smith Technologies to Francisco Partners
Davis Polk is advising J M Smith Corporation in connection with the sale of its technologies division, Smith Technologies,…
NuVasive $450 million convertible senior notes offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by NuVasive, Inc. of $450 million…
Atara Biotherapeutics $100 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Atara Biotherapeutics, Inc. of its common…
CytomX Therapeutics $75 million at-the-market offering
Davis Polk advised the sales agent in connection with the SEC-registered at-the-market offering by CytomX Therapeutics, Inc…
BioXcel Therapeutics $73.6 million stock offering
Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,300…
Revolution Medicines $273.7 million IPO
Davis Polk advised the underwriters in connection with an initial public offering of 16,100,000 shares of common stock of…
Revance Therapeutics $287.5 million convertible senior notes offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Revance Therapeutics, Inc. of $287.5…
Shockwave Medical $16.5 million supplemental term loan
Davis Polk advised Shockwave Medical, Inc. in connection with a $16.5 million supplemental term loan provided by Silicon…
Theravance Biopharma $148.5 million follow-on offering
Davis Polk advised the underwriters in connection with the $148.5 million public offering of ordinary shares by…